Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cullinan Therapeutics (CGEM) Gains from Investment Securities (2020 - 2023)

Cullinan Therapeutics has reported Gains from Investment Securities over the past 4 years, most recently at -$9.1 million for Q4 2023.

  • Quarterly results put Gains from Investment Securities at -$9.1 million for Q4 2023, up 53.08% from a year ago — trailing twelve months through Dec 2023 was -$4.4 million (down 133.84% YoY), and the annual figure for FY2025 was $100.0, up 100.0%.
  • Gains from Investment Securities for Q4 2023 was -$9.1 million at Cullinan Therapeutics, down from $4.6 million in the prior quarter.
  • Over the last five years, Gains from Investment Securities for CGEM hit a ceiling of $32.7 million in Q3 2022 and a floor of -$19.5 million in Q4 2022.
  • Median Gains from Investment Securities over the past 4 years was $1.8 million (2021), compared with a mean of $2.9 million.
  • Biggest five-year swings in Gains from Investment Securities: tumbled 282.07% in 2022 and later surged 4350.46% in 2023.
  • Cullinan Therapeutics' Gains from Investment Securities stood at $4.6 million in 2020, then surged by 132.46% to $10.7 million in 2021, then tumbled by 282.07% to -$19.5 million in 2022, then surged by 53.08% to -$9.1 million in 2023.
  • The last three reported values for Gains from Investment Securities were -$9.1 million (Q4 2023), $4.6 million (Q2 2023), and $75000.0 (Q1 2023) per Business Quant data.